297 related articles for article (PubMed ID: 8749840)
1. GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline.
Todd KG; Baker GB
J Affect Disord; 1995 Dec; 35(3):125-9. PubMed ID: 8749840
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin.
Todd KG; Baker GB
J Pharm Pharm Sci; 2008 May; 11(2):14s-21s. PubMed ID: 19203467
[TBL] [Abstract][Full Text] [Related]
3. Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.
MacKenzie EM; Grant SL; Baker GB; Wood PL
Neurochem Res; 2008 Mar; 33(3):430-6. PubMed ID: 17768678
[TBL] [Abstract][Full Text] [Related]
4. Effects of the MAO inhibitor phenelzine on glutamine and GABA concentrations in rat brain.
Paslawski TM; Sloley BD; Baker GB
Prog Brain Res; 1995; 106():181-6. PubMed ID: 8584653
[TBL] [Abstract][Full Text] [Related]
5. Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-transaminase activity in rat brain.
McManus DJ; Baker GB; Martin IL; Greenshaw AJ; McKenna KF
Biochem Pharmacol; 1992 Jun; 43(11):2486-9. PubMed ID: 1610412
[TBL] [Abstract][Full Text] [Related]
6. The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors.
Alemany R; Olmos G; García-Sevilla JA
Br J Pharmacol; 1995 Feb; 114(4):837-45. PubMed ID: 7773544
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent changes in brain monoamine oxidase activity and in brain levels of monoamines and amino acids following acute administration of the antidepressant/antipanic drug phenelzine.
Parent MB; Habib MK; Baker GB
Biochem Pharmacol; 2000 May; 59(10):1253-63. PubMed ID: 10736426
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function.
McKenna KF; McManus DJ; Baker GB; Coutts RT
J Neural Transm Suppl; 1994; 41():115-22. PubMed ID: 7931216
[TBL] [Abstract][Full Text] [Related]
10. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
Celada P; Artigas F
J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
[TBL] [Abstract][Full Text] [Related]
11. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
Cabanillas AM; Masini-Repiso AM; Costamagna ME; Pellizas C; Coleoni AH
J Endocrinol; 1994 Nov; 143(2):303-8. PubMed ID: 7829993
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
Lenzen S; Nahrstedt H; Panten U
Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors.
Fagervall I; Ross SB
Biochem Pharmacol; 1986 Apr; 35(8):1381-7. PubMed ID: 2870717
[TBL] [Abstract][Full Text] [Related]
14. Effect of nonselective and selective inhibitors of monoamine oxidases A and B on pethidine toxicity in mice.
Boden R; Botting R; Coulson P; Spanswick G
Br J Pharmacol; 1984 May; 82(1):151-4. PubMed ID: 6428496
[TBL] [Abstract][Full Text] [Related]
15. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.
Matveychuk D; MacKenzie EM; Kumpula D; Song MS; Holt A; Kar S; Todd KG; Wood PL; Baker GB
Cell Mol Neurobiol; 2022 Jan; 42(1):225-242. PubMed ID: 33839994
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine.
Baker G; Matveychuk D; MacKenzie EM; Holt A; Wang Y; Kar S
Chem Biol Interact; 2019 May; 304():139-147. PubMed ID: 30857888
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of the antidepressant-antipanic drug phenelzine and its N-acetylated analogue: effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function.
McKenna KF; Baker GB; Coutts RT; Greenshaw AJ
J Pharm Sci; 1992 Aug; 81(8):832-5. PubMed ID: 1383493
[TBL] [Abstract][Full Text] [Related]
18. Task-dependent effects of the antidepressant/antipanic drug phenelzine on memory.
Parent MB; Habib MK; Baker GB
Psychopharmacology (Berl); 1999 Mar; 142(3):280-8. PubMed ID: 10208320
[TBL] [Abstract][Full Text] [Related]
19. Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum.
Parent MB; Master S; Kashlub S; Baker GB
Biochem Pharmacol; 2002 Jan; 63(1):57-64. PubMed ID: 11754874
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
